F-14/15, Orbit Mall, Civil Lines, Jaipur-302006
support@thetaxheaven.com
F-14/15, Orbit Mall, Civil Lines, Jaipur-302006 support@thetaxheaven.comPoly Medicure Ltd, a leading name in the Indian medical devices sector, has gained considerable traction among investors for its consistent performance, strong fundamentals, and future growth potential. With its vast product portfolio, global exports, and steady R&D investments, the company is positioned as a long-term growth candidate on the NSE and BSE. In this article, we will explore Poly Medicure’s share price targets from 2025 to 2030, key financials, and investment outlook.
Let’s dive into the stock’s recent performance and future share price forecast.
| Detail | Value |
|---|---|
| Open Price | ₹1,964.00 |
| Previous Close | ₹1,948.60 |
| Day’s High | ₹2,049.90 |
| Day’s Low | ₹1,928.10 |
| VWAP | ₹1,992.11 |
| 52-Week High | ₹3,357.80 |
| 52-Week Low | ₹1,810.15 |
| All Time High | ₹3,357.80 |
| All Time Low | ₹22.64 |
| Market Capitalization | ₹20,528 Cr |
| Face Value | ₹5 |
| Beta (Volatility) | 0.92 |
| Dividend Yield | 0.17% |
| Book Value per Share | ₹255.74 |
| Volume | 99,515 |
| 20D Avg Volume | 111,721 |
| 20D Avg Delivery % | 65.98% |
Established in 1995, Poly Medicure Ltd (commonly known as Polymed) is a prominent manufacturer and exporter of medical devices, particularly in the IV therapy, oncology, urology, and blood management sectors. The company has manufacturing facilities in India and abroad and exports to over 110 countries, making it a well-diversified healthcare player.
25+ years of expertise in medical devices
Strong in-house R&D and product innovation
Export-driven revenue with global presence
Focus on sustainable manufacturing and automation
Increasing demand for disposable medical devices post-pandemic
| Investor Type | Holding (%) |
|---|---|
| Promoters | 62.44% |
| Retail and Others | 14.44% |
| Foreign Institutions | 11.41% |
| Mutual Funds | 7.34% |
| Other Domestic Institutions | 4.38% |
This strong promoter holding combined with significant institutional interest reflects investor confidence in the company’s long-term growth.
| Year | Minimum Target (₹) | Maximum Target (₹) |
|---|---|---|
| 2025 | 1,980 | 2,150 |
| 2026 | 2,200 | 2,480 |
| 2027 | 2,450 | 2,770 |
| 2028 | 2,750 | 3,050 |
| 2029 | 3,000 | 3,350 |
| 2030 | 3,300 | 3,750 |
These price targets are based on Poly Medicure’s revenue growth, industry trends, innovation in product lines, and increasing global demand for healthcare devices.
The company is expected to see moderate recovery in 2025 after a correction phase in 2024.
Why?
Stabilization after a fall from all-time highs
Increased exports to Europe and Africa
Strategic focus on oncology and dialysis devices
Investment Advice: Accumulate during dips. Good entry point for long-term investors.
With robust demand and capacity expansion, 2026 is likely to be a growth year.
Why?
Higher operational efficiency
Expansion of manufacturing units in India
Favourable government policies for healthcare exports
Investment Advice: Hold or accumulate more if trend remains upward. Ideal for SIPs.
Innovation in product lines could drive up revenue and stock performance.
Why?
Introduction of AI-integrated medical devices
Boost in disposable device consumption globally
Medical tourism growth in India
Investment Advice: Hold and consider dividend reinvestment. Track quarterly earnings closely.
Strong sales momentum could help breach the ₹3,000 mark.
Why?
Government support for Make in India healthcare
Rising hospital infrastructure in Tier 2/3 cities
Strengthening of distribution network
Investment Advice: Long-term investors may benefit from compounding returns. Stay invested.
2029 could mark an important turning point as Polymed reaches global top-tier status.
Why?
Expansion into Latin America and Eastern Europe
Improved EPS and lower debt ratios
Increase in institutional holding
Investment Advice: Hold for the long term. Maintain portfolio allocation between healthcare and other sectors.
By 2030, Poly Medicure is expected to be among the global leaders in niche medical devices.
Why?
Strong international presence
High-margin product categories like oncology
Ongoing investment in sustainable manufacturing
Investment Advice: Consider it a core holding for long-term wealth creation.
Yes. Poly Medicure offers a compelling investment case due to its:
Niche leadership in medical devices
Strong financials and low beta (0.92, indicating less volatility)
R&D-driven business model
Consistent promoter and institutional support
The company is well-positioned to benefit from global healthcare demand and India’s growing role in medical device manufacturing.
Global regulatory changes in medical devices
High dependence on export markets
Currency fluctuations
Competitive pressure from global giants
Always consider risk management strategies and diversify your portfolio.
Poly Medicure Ltd stands out as a promising mid-cap stock with strong fundamentals, a visionary leadership team, and a robust growth outlook. With a market cap of ₹20,528 Cr and a solid base in both domestic and export markets, it has the potential to reach ₹3,750 per share by 2030 if current growth trajectories are sustained.
Investors with a long-term horizon and a moderate risk appetite may consider adding Poly Medicure to their core portfolio for sustained returns in the booming healthcare sector.
What is Poly Medicure’s share price target for 2025?
Analysts expect the stock to range between ₹1,980 and ₹2,150 by 2025.
Is Poly Medicure a good investment?
Yes, especially for long-term investors interested in the healthcare and medical device sector.
What is the shareholding pattern of Poly Medicure Ltd?
Promoters hold 62.44%, and institutions like mutual funds and FIIs hold over 18%.
What is the dividend yield of Poly Medicure?
Currently, the dividend yield is approximately 0.17%.
Has Poly Medicure reached its all-time high?
Yes, its all-time high was ₹3,357.80.
Does Poly Medicure export products globally?
Yes, it exports to over 110 countries and earns a significant portion of its revenue from international markets.
What are the key growth drivers for Poly Medicure?
R&D, global healthcare demand, government support, and product innovation.
Is the stock volatile?
With a beta of 0.92, it shows relatively lower volatility compared to market averages.
Disclaimer: This article is for educational purposes only. Investors should do their own research or consult a financial advisor before making investment decisions.
Register & Login